CSL Limited has opened a new $230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows, Vic.
Created with "significant support from the Victorian Government," the project will help meet growing global demand for albumin, a protein derived from human plasma, used for burns and shock.
When fully operational, with the opening of two modules, the facility will expand CSL's albumin capabilities to 200 tonnes annually and will export product to the US and Europe as well as serving the Australian and Asia Pacific market.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Dec 17
